Mutational Analysis of the PTEN Gene in Endometrial Carcinoma and Hyperplasia

American Journal of Clinical Pathology

Volumn 115, Issue 1, 2001, Pages 32-38

  Sun, Hongbo ^a   Enomoto, Takayuki ^a   Fujita, Masami ^a   Wada, Hiroko ^a   Yoshino, Kiyoshi ^a   Ozaki, Keiichiro ^a   Nakamura, Takafumi ^a   Murata, Yuji ^a  

^a NONE

Author keywords

Endometrial carcinoma; Endometrial hyperplasia; Etiology; PTEN; Single strand conformation polymorphism; SSCP

Indexed keywords

PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; MOLECULAR CLONING; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL;

CARCINOMA; CLONING, MOLECULAR; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0035220843     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7JX6-B9U9-3P0R-EQNY     Document Type: Article

References (32)

1. Barrett RJ II, Harlan LC, Wesley MN, et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am J Obstet Gynecol. 1995;173:414-422.
2. Masubuchi K. Increasing incidences of endometrial carcinoma in Japan. Gynecol Oncol. 1975;3:335-346.
3. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 proto-oncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 1993;53:1883-1888.
4. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res. 1993;53:5100-5103.
5. Jones MH, Koi S, Fujimoto I, et al. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer. 1994;9:119-123.
6. Peiffer SL, Herzog TJ, Tribune DJ, et al. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995;55:1922-1926.
7. Li J, Yen C, Liaw D. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947.
8. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356-362.
9. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1997;94:9052-9057.
10. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A. 1998;95:13513-13518.
11. Stambolic V, Suzuki A, Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29-39.
12. Guldberg P, Straten PT, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660-3663.
13. Rasheed BKA, Stenzel TT, McLendon RE, et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997;57:4187-4190.
14. Gray IC, Stewart LMD, Phillips SMA, et al. Mutation and expression analysis of the putative prostate tumor-suppressor gene PTEN. Br J Cancer. 1998;78:1296-1300.
15. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-3940.
16. Liaw D, Marsh DJ, Li J. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64-67.
17. Nelen MR, Staveren WCG, Peeters EAJ, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6:1383-1387.
18. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57:4736-4738.
19. Kurose K, Bando K, Fukino K, et al. Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidences for inactivation of both alleles. Jpn J Cancer Res. 1998;89:842-848.
20. Kong D, Suzuki A, Zou T. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997;17:143-144.
21. Simpkins SB, Peiffer-Schneider S, Mutch DG, et al. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol. 1998;71:391-395.
22. Lin WM, Forgacs E, Warshal DP, et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res. 1998;4:2577-2583.
23. Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58:2500-2503.
24. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4:3005-3010.
25. Capella G, Cronauer-Mitra S, Peinado MA, et al. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect. 1991;93:125-131.
26. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991;350:427-428.
27. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429-431.
28. Hosono S, Chou MJ, Lee CS, et al. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene. 1993;8:491-496.
29. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and activation of c-K-ras-2 proto-oncogene in endometrial adenocarcinoma from Colorado. Am J Clin Pathol. 1995;103:224-230.
30. Kurman RJ, Karminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of untreated hyperplasia in 170 patients. Cancer. 1985;56:403-412.
31. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58:3254-3258.
32. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012-1019.